Latest Breaking News On - Cancer fact - Page 1 : comparemela.com

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting .

Kunlun
Zhejiang
China
Spain
Australia
Canada
United-states
Sweden
Japan
United-kingdom
San-francisco
California

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Sweden
Cambridge
Cambridgeshire
United-kingdom
Italy
Canada
Australia
Kunlun
Zhejiang
Japan
United-states

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial | Antibodies

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

China
London
City-of
United-kingdom
Canada
Kunlun
Zhejiang
South-korea
Cambridge
Cambridgeshire
Italy
Sweden

AstraZeneca (AZN) announces IMFINZI plus bevacizumab met primary endpoint for PFS in liver cancer eligible for embolization in EMERALD-1 Phase III trial

AstraZeneca (AZN) announces IMFINZI plus bevacizumab met primary endpoint for PFS in liver cancer eligible for embolization in EMERALD-1 Phase III trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Australia
United-states
Japan
South-korea
Taiwan
Kunlun
Zhejiang
Canada
United-kingdom
Cambridge
Cambridgeshire

AstraZeneca: Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers

AstraZeneca: Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers
privataaffarer.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from privataaffarer.se Daily Mail and Mail on Sunday newspapers.

Japan
United-states
United-kingdom
China
South-africa
Cambridge
Cambridgeshire
Canada
Switzerland
America
American
Dave-fredrickson